SCHEMBL25348200

SCHEMBL25348200

CN(C)CC(F)CN(Cc1ccccc1)Cc1ccccc1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TSHR P16473 3/20 0.52
ALDH1A1 P00352 2/20 0.52
HTR2A P28223 2/20 0.44
HRH1 P35367 1/20 0.44
AOC3 Q16853 1/20 0.44
TDP1 Q9NUW8 1/20 0.42
ADRA2B P18089 1/20 0.42
ADRA2C P18825 1/20 0.42
SLC6A2 P23975 1/20 0.42
SLC6A4 P31645 1/20 0.42
ADRA1A P35348 1/20 0.42
OPRK1 P41145 1/20 0.42
SLC6A3 Q01959 1/20 0.42
KCNH2 Q12809 1/20 0.42
TAAR1 Q96RJ0 2/20 0.41
KDM4E B2RXH2 2/20 0.41
CNR2 P34972 1/20 0.41
MGLL Q99685 1/20 0.41
SMN1; SMN2 Q16637 1/20 0.40
CARM1 Q86X55 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6251771 0.90 ALDH1A1 (0.44) TSHRALDH1A1HTR2AAOC3ADRA2B
SCHEMBL10315714 0.83 KDM4E (0.46) TSHRALDH1A1HTR2AAOC3ADRA2B
SCHEMBL15688749 0.82 POLB (0.42) TSHRALDH1A1HTR2AAOC3ADRA2B
SCHEMBL21328902 0.82 POLB (0.42) TSHRALDH1A1HTR2AAOC3ADRA2B
SCHEMBL15688747 0.82 POLB (0.42) TSHRALDH1A1HTR2AAOC3ADRA2B
SCHEMBL12881360 0.81 SLC6A2 (0.44) TSHRALDH1A1HTR2AAOC3ADRA2B
SCHEMBL28586963 0.81 ALDH1A1 (0.40) TSHRALDH1A1HTR2AAOC3ADRA2B
SCHEMBL21379192 0.81 TSHR (0.41) TSHRALDH1A1HTR2AAOC3ADRA2B
SCHEMBL83748 0.79 PNP (0.43) TSHRALDH1A1TDP1OPRK1KDM4E
SCHEMBL13657504 0.79 PNP (0.43) TSHRALDH1A1TDP1OPRK1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240043420-A1 7-AZAINDOLE COMPOUNDS FOR INHIBITION OF BCR-ABL TYROSINE KINASES ENLIVEN INC. 2024-02-08 US disclosed
EP-4225741-A1 7-AZAINDOLE COMPOUNDS FOR INHIBITION OF BCR-ABL TYROSINE KINASES Enliven Therapeutics, Inc. (US) 2023-08-16 EP disclosed
CN-116438182-A 7-azaindole compounds for inhibiting BCR-ABL tyrosine kinase 活力疗法公司 2023-07-14 CN disclosed
WO-2022076973-A1 7-AZAINDOLE COMPOUNDS FOR INHIBITION OF BCR-ABL TYROSINE KINASES ENLIVEN THERAPEUTICS, INC. (US) 2022-04-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240043420-A1 7-AZAINDOLE COMPOUNDS FOR INHIBITION OF BCR-ABL TYROSINE KINASES ABL1, ABL2, BCR TSHR 3894/4885ALDH1A1 1355/4885HTR2A 3696/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.